Hao, Huai-Xiang <br/><br/>
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.  [electronic resource] 

 -  Molecular cancer therapeutics  12 2019 
 - 2368-2380 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-19-0170  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Cell Line, Tumor<br/>Disease Models, Animal<br/>Female<br/>Humans<br/>Mice<br/>Neoplasms--drug therapy<br/>Protein Tyrosine Phosphatase, Non-Receptor Type 11--antagonists & inhibitors<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Signal Transduction<br/>Tachykinins--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays